SWOG clinical trial number
SWOG-8393 (INT-0013)
National Intergroup Protocol for Intermediate Thickness Melanomas 1.0 to 4.0 mm (MEL 82 323)
Closed
Phase
Published
Abbreviated Title
National Intergroup Protocol for Intermediate Thickness Melanomas 1.0 to 4.0 mm (MEL 82 323)
Activated
07/07/1983
Closed
03/15/1992
Research committees
Melanoma
Publication Information Expand/Collapse
2000
Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm)
1996
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 year of age and younger.
Surgical therapy of primary cutaneous melanoma.
Local recurrence in malignant melanoma: Long-term results of the multiinstitutional randomized surgical trial.
1995
Local recurrence in malignant melanoma: Long-term results of the surgical trial.
A centimeter here, a centimeter there: Does it matter?
1993
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1-4 mm): Results of multi-institutional randomized surgical trial.
Other Clinical Trials
SWOG Clinical Trial Number
S2000
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Research Committee(s)
Melanoma
Activated
09/23/2020
Accrual
100%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6174
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase